1
Xuenong Xu: Preparation method of ticagrelor and intermediates thereof. SUZHOU MIRACPHARMA TECHNOLOGY, Perkins Coie, March 28, 2017: US09604991

Disclosed in the present invention is a method for preparing Ticagrelor (I), comprising the following steps: a cyclization reaction of 5-amino-1,4-di-substituted-1,2,3-triazole (II) and dialkyl carbonate (HI), to obtain 9-substituted-2,6-dihydroxy-8-azapurine (IV); chlorination of intermediate (IV), ...


2
Xuenong Xu: Method for preparing Ibrutinib. SUZHOU MIRACPHARMA TECHNOLOGY, Perkins Coie, March 21, 2017: US09598425

Provided is a method for preparing Ibrutibin (I), and steps of preparing same comprise: 4-benzyloxybenzoyl chloride (II) is used as a raw material, condensation and methoxidation reactions occur among 4-benzyloxybenzoyl chloride (II), malononitrile, and dimethyl sulfate to generate 4-benzyloxyphenyl ...


3
Xuenong Xu: Method for preparing Palbociclib. SUZHOU MIRACPHARMA TECHNOLOGY, Perkins Coie, June 26, 2018: US10005778

This invention reveals the method for preparing Palbociclib (I). The preparation includes: produce the 6-acetyl-5-methyl-2-substituent-pyrido[2,3-d]pyrimidin-7(8H)-one (IV) through the ring-closure reaction by using accessible raw materials of 1-(4-amino-2-substituent-5-pyrimidinyl) ethanone (II) an ...


4
Xuenong Xu: Avanafil preparation method. SUZHOU MIRACPHARMA TECHNOLOGY, Perkins Coie, September 27, 2016: US09453001

Disclosed is a method for preparing avanafil (I) by using cytosine as the starting material. The preparation steps comprise: using cytosine as the raw material, and enabling the cytosine to react with side chain 3-chlorine-4-methoxybenzyl halogen, N-(2-methylpyrimidine) methanamide and S-hydroxymeth ...


5
Xuenong Xu: Ribociclib intermediate and preparation method therefor. SUZHOU MIRACPHARMA TECHNOLOGY, Perkins Coie, June 26, 2018: US10005726

Disclosed are an intermediate N-cyclopentyl-2-methoxy-5-(N,N-dimethyl-formamido)-3-pyrrylformonitrile (II) for preparing ribociclib and a preparation method therefor. The preparation method comprises the following preparation steps: carrying out halogenating reaction on N,N-dimethyl-2-carbonyl-propa ...


6
Xuenong Xu: Avanafil preparation method. SUZHOU MIRACPHARMA TECHNOLOGY, Perkins Coie, March 14, 2017: US09593101

Disclosed is a method for preparing avanafil (I) by using cytosine as the starting material. The preparation steps comprise: using cytosine as the raw material, and enabling the cytosine to react with side chain 3-chlorine-4-methoxybenzyl halogen, N-(2-methylpyrimidine)methanamide and S-hydroxymethy ...


7
XU Xuenong: [zh] 阿伐那非的制备方法, [fr] PROCÉDÉ DE PRÉPARATION DAVANAFIL, [en] AVANAFIL PREPARATION METHOD. SUZHOU MIRACPHARMA TECHNOLOGY, XU Xuenong, SUZHOU WISTONG INTELLECTUAL PROPERTY AGENCY, November 27, 2014: WO/2014/187273

[en] Disclosed is a method for preparing avanafil (I) by using cytosine as the starting material. The preparation steps comprise: using cytosine as the raw material, and enabling the cytosine to react with side chain 3-chlorine-4-Methoxybenzyl halogen, N-(2-methylpyrimidine) methanamide, and S-hydro ...


8
XU XUENONG: [ZH] 抗血小板药物AZD6482的制备方法, [EN] Preparation method for antiplatelet medicine AZD6482. SUZHOU MIRACPHARMA TECHNOLOGY, ding xiuhua, May 6, 2015: CN133659605

[EN] The invention discloses a preparation method for an antiplatelet medicine AZD6482 (I). The preparation method comprises the following preparation steps: preparing from common chemical raw materials such as propionaldehyde and acetoacetamide to obtain an important intermediate 3-acetyl-5-methyl- ...


9
XU XUENONG: [ZH] 玻玛西尼的制备方法, [EN] Preparing method for bemaciclib. SUZHOU MIRACPHARMA TECHNOLOGY, ding xiuhua, April 22, 2015: CN133466448

[EN] The invention discloses a bemaciclib or abemaciclib middle body and a preparing method thereof. The preparing method comprises the steps that condensation, amidine reaction, cyclization and other unit reactions are carried out; the bemaciclib or abemaciclib middle body serves as a raw material, ...


10
AVANAFIL PREPARATION METHOD. SUZHOU MIRACPHARMA TECHNOLOGY, March 17, 2016: US20160075693-A1

Disclosed is a method for preparing avanafil (I) by using cytosine as the starting material. The preparation steps comprise: using cytosine as the raw material, and enabling the cytosine to react with side chain 3-chlorine-4-methoxybenzyl halogen, N-(2-methylpyrimidine) methanamide and S-hydroxymeth ...